Shares of orthopedic device makers are up this morning after bellwether Biomet Inc. reported preliminary sales numbers indicating 3.8 percent growth for its fiscal second quarter.
Biomet
Acquisitions, buybacks and dividends slated to grow, Moody’s says | MassDevice.com On Call
MASSDEVICE ON CALL — U.S. med-tech makers are likely to invest in buyback programs and acquisitions and to pursue dividends to maintain shareholder value, according to Moody’s Investors Service.
As pricing pressures continue to weigh on the industry and demand remains soft, medical device makers are likely to look elsewhere to spur growth and keep stakeholders happy.
Sector revenue growth may also remain soft thanks to a weak global economy, MarketWatch reported.
Replacement hip makers scale back doc payments after kickback scandal | MassDevice.com On Call
MASSDEVICE ON CALL — The top artificial hip and knee makers cut spending on consultants after a federal case charged them with providing illegal kickbacks.
Biomet’s Q1 sales tick up, but losses widen 120 percent | Earnings Roundup
Biomet Inc.’s first-quarter losses widened significantly despite nearly 4 percent top-line growth during the three months ended August 31.
The privately owned orthopedics giant posted losses of $39 million on sales of $665 million during the quarter, up 120.2 percent and 3.7 percent, respectively, over Q1 2011.
Biomet’s Q1 sales tick up, but losses widen 120 percent
Biomet Inc.’s first-quarter losses widened significantly despite nearly 4 percent top-line growth during the three months ended August 31.
The privately owned orthopedics giant posted losses of $39 million on sales of $665 million during the quarter, up 120.2 percent and 3.7 percent, respectively, over Q1 2011.
Biomet: $775,000,000 10 percent senior notes due 2017
Table of Contents
Filed Pursuant to Rule 424(b)(2)
Registration No. 333-150655
Stryker/Biomet’s rumored affair with SNN, massage strangler warnings, breast implants, the best of the summer, med-tech spending cuts and Stryker’s overseas efforts made headlines this week | MassDevice.com +7
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with Massdevice +7.
Acquisition rumors for SNN by Biomet or Stryker, J&J under pressure to recall silicone breast implants, Medtronic and NuVasive rekindle patent spat | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.
Stryker or Biomet to buy Smith & Nephew?
Hip implant recall on track to be costliest device issue since Medtronic’s Sprint Fidelis | MassDevice.com On Call
MASSDEVICE ON CALL — Metal-on-metal hip implants complaints have skyrocketed in recent months, numbering more than 5,000 since January, which is more than for the past four years combined.
Hip replacements are one of the most common procedures in the U.S., and one estimate puts the number of patients with metal-on-metal implants at 500,000.
Eye and ear implants blow away hearts and hips for most frequently implanted medical devices in the U.S.
Eye and ear devices are the most implanted medical devices in the U.S., according to a new study by financial news and opinion company 24/7 Wall St.
Artificial eye lenses for the treatment of cataracts topped the list of the 11 most frequently implanted medical devices in the U.S. with more than 2.5 million surgeries performed annually at a rate of about $3,200 to $4,500 per eye, depending on the type of lens. Total expenditure was estimated at between $8 billion and $10 billion per year.